Table 4.
Changes on clinical and biochemical parameters after zinc supplementation according to +1245 MT1A A/G genotypes
| G− genotype | G+ genotype | p value | |
|---|---|---|---|
| CRP (mg/dL) | 62.8 ± 25.9 | −1.4 ± 11.1 | 0.35 |
| Albumin (g/dL) | 2.5 ± 0.95 | 5.2 ± 2.2 | 0.28 |
| Glycemia (mg/dL) | −1.75 ± 1.9 | −1.0 ± 2.8 | 0.95 |
| Total cholesterol (mg/dL) | −0.1 ± 1.4 | 1.3 ± 3.0 | 0.82 |
| HDL-cholesterol (mg/dL) | 6.4 ± 1.7 | 4.3 ± 2.1 | 0.81 |
| AGEs (ng/mL) | 8.3 ± 7.0 | −19.8 ± 15.6 | 0.12 |
| ROS (MFI) | 8.2 ± 6.9 | −22.4 ± 19.3 | 0.14 |
| pSOD (U/mL) | 14.9 ± 1.2 | 18.4 ± 2.6 | 0.28 |
| GPx (nmol NADPH/min/mL) | −0.76 ± 0.22 | 0.11 ± 0.45 | 0.086 |
| CAT (μmol/min/mg prot) | −8.9 ± 1.1 | −9.4 ± 2.3 | 0.64 |
| Zn plasma levels (μM) | 9.3 ± 2.1 | 4.5 ± 2.9 | 0.50 |
| Zn granulocytes (nmol/mg protein) | 83.3 ± 21.7 | 163.9 ± 43.3 | 0.14 |
| MT (MFI) | 64.5 ± 28.4 | 31.9 ± 67.4 | 0.58 |
| iZnL | 7.0 ± 2.3 | 19.8 ± 5.6 | 0.020 |
| iZnR | 14.5 ± 7.5 | 60.3 ± 14.6 | 0.031 |
Data are mean of % changes ± SE
Comparisons between G+ (AG+GG) and G− (AA) genotype were performed by ANCOVA analysis correcting for age, gender and country
Bold values indicate a significant difference